Revive Therapeutics Ltd. (CSE: RVV)

Shares :

INVESTOR PROFIL

REVIVE THERAPEUTICS LTD


SYMBOL :                                               RVV |  RVVTF

SECTOR :                                               LIFE SCIENCE

O/S :                                                        72,4 M

MARKET CAP :                                      $ 5,4 M

MARKET OPPORTUNITY :                   UP TO $180 B

REVIVE THERAPEUTICS LTD is as unique opportunity to invest in the next evolution of the cannabis and psychedelic market

Michael Frank, Chief Executive Officer of Revive

 

Revive is leveraging its unique intellectual property portfolio and is focusing its efforts on building a pipeline of cannabinoid- based treatments for rare inflammatory diseases targeting multi-billion dollar markets

COMPANY BRIEF

 

| Emerging cannabis and psychedelic life sciences company

| Developing novel cannabis and psychedelic based therapies to treat liver, inflammatory, and rare diseases

| Robust cannabis and psychedelic based product portfolio targeting multi-billion market opportunities

| Significantly undervalued compared to cannabis-based biopharma peers

| Unique opportunity to invest in the next evolution of the cannabis and psychedelic market

HIGHLIGHTS

 

| 4 Exclusive licenses to patents in delivery system and liver disease

| 2 FDA orphan drug designation for CBD in treatment of AIH and prevention IRI from solid organ transplantation

| Exclusive Worldwide License Agreement with WARF (cannabinoid delivery technology)

| 7 Strategic relationships

| Market opportunity up to $180 Billions

UPDATE | NEW PSYCHEDELIC OPPORTUNITY 

PSYCHEDELIC HIGHLIGHTS

 

| Entered into LOI to acquire Psilocin Pharma Corp. (PPC)

| PPC has novel methods of production of Psilocybin-based formulations

| Developed six unique formulations for both natural and synthetically derived Psilocybin

| Mental Health (450mm population) | Eating Disorders (70mm population) | Addiction (240mm population)

PSYCHEDELIC PRODUCTS

 

| PSILOCYBIN CAPSULES (PSY-0.1)

| PSILOCYBIN SUBLINGUAL SPRAY (PSY-0.2)

| PSILOCYBIN GEL CAP (PSY-0.3)

| PSILOCYBIN EFFERVESCENT TABLETS (PSY-0.4/0.5)

| PSILOCYBIN ORAL FAST DISSOLVING STRIP (PSY-0.6)

STRATEGIC RELATIONSHIPS

UNDERVALUED VS PEERS

VALUE DRIVING MILESTONES IN 2020

RVV | CSE

RVV | OTC

JOIN FACEBOOK INVESTOR GROUP


Shares :